Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending May 31, 2019
27 July 2019 - 6:45AM
Business Wire
Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the
“Company” or “Bioasis”), a pre-clinical, research-stage
biopharmaceutical company developing its proprietary
xB3™ platform technology
for the delivery of therapeutics across the blood-brain barrier
(“BBB”) and the treatment of central nervous system (“CNS”)
disorders in areas of high unmet medical need, including brain
cancers and neurodegenerative diseases, today announced it has
filed its unaudited quarterly financial statements and management’s
discussion and analysis for the period ended May 31, 2019. All are
available under the Company’s profile on SEDAR at www.sedar.com and
on the Company’s website at www.bioasis.us/investors/.
On behalf of the Board of Directors of Bioasis Technologies
Inc.
Deborah Rathjen, Ph.D., Director and President & Chief
Executive Officer
ABOUT BIOASIS Bioasis Technologies Inc. is a
biopharmaceutical company developing the xB3™ platform, a proprietary technology
for the delivery of therapeutics across the BBB and the treatment
of CNS disorders in areas of high unmet medical need, including
brain cancers and neurodegenerative diseases. The delivery of
therapeutics across the BBB represents the final frontier in
treating neurological disorders. The in-house development programs
at Bioasis are designed to develop symptomatic and
disease-modifying treatments for brain-related diseases and
disorders. The company maintains headquarters in Guilford, Conn.,
United States. Bioasis trades on the TSX Venture Exchange under the
symbol “BTI” and on the OTCQB under the symbol “BIOAF.” For more
information about the company, please visit www.bioasis.us.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190726005446/en/
Deborah Rathjen, Ph.D. deborah@bioasis.us +1 203 533 7082
BiOasis Technologies (TSXV:BTI)
Historical Stock Chart
From Jan 2025 to Feb 2025
BiOasis Technologies (TSXV:BTI)
Historical Stock Chart
From Feb 2024 to Feb 2025
